SOURCE: Streetwise Reports

Streetwise Reports

April 21, 2016 09:00 ET

UCLA's Dr. Stuart Holden Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - April 21, 2016) - Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose -- a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men.

Included in this interview is: Arno Therapeutics Inc. (OTCQB: ARNI).

The Life Sciences Report : You've worked on the front lines of prostate cancer for more than 36 years. What is the most dramatic change you've seen?

Stuart Holden: I don't know if it's the most dramatic, but I would say the most game-changing was the development of the prostate specific antigen (PSA) assay. It was developed academically around 1977, and it was a true early biotechnology story. It took until the mid- or late 1980s before the PSA started creeping into routine clinical practice. It was a huge game changer in the sense that maybe 10% of my patient population was devoted to prostate cancer patients before the PSA assay, but since its introduction, I would say 80% of my patients fall into that category. I specialize in that area as a genitourinary oncologist, so my experience is a little biased, but that's the way it is today.

The PSA has been both heralded and demonized. It's been used properly and misused. But during the PSA era, the death rate from prostate cancer has gone down 40%. The PSA has also led to over diagnosis and overtreatment -- all of that is true. But at the end of the day, PSA is still the best biomarker in clinical utilization. I believe the single greatest reason for that reduction in deaths was…

Continue reading this interview: What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Arno Therapeutics Inc. is a billboard advertiser with Streetwise Reports. Dr. Stuart Holden had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Stuart Holden and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information